A bacterial enzyme may be a future candidate in smoking cessation, according to a new study led by researchers at The Scripps Institute. Findings from the study are published in the Journal of the American Chemical Society.
Current smoking cessation aids have proven to be ineffective in at least 80–90% of smokers. This novel enzyme therapy would be to eliminate nicotine before it reaches the brain as to not trigger a smoker into relapse. The NicA2 enzyme is found in the, which is originally from soil in a tobacco field. The bacteria consumes nicotine as its one source of carbon and nitrogen. Researchers set out to test its potential efficacy as a therapeutic agent.
The team combined serum from mice with a nicotine dose equivalent to one cigarette. When the enzyme was added, they found the nicotine's half-life was cut from 2–3 hours to just 9–15 minutes. A higher dose of the enzyme could decrease the half-life of nicotine even more and prevent it from reaching the brain. The team then tested the enzyme to assess its practicality as a drug candidate. The enzyme remained stable in the lab for over three weeks at 98 degrees Fahrenheit. Also, the scientists did not find any toxic metabolites produced when the enzyme broke down nicotine.
Future studies will include improving the enzyme's serum stability so that a single injection can last up to a month, researchers concluded.Read more..
Blood lipid profiles are associated with childhood asthma, airway obstruction, bronchial responsiveness, and aeroallergen sensitization, researchers from Denmark report.
Dr. Hans Bisgaard from the University of Copenhagen told Reuters Health by email that he was surprised by the "significant association between serum lipids and asthma and allergy. This association is similar to the association found between serum lipids and other chronic inflammatory disorders."
Previous studies examining the relationship between the blood lipids and asthma have yielded ambiguous results, despite the association of hypercholesterolemia with a skewing of the adaptive immune response toward a TH2-oriented response, which is also seen in asthma and related disorders.
Dr. Bisgaard's team investigated the possible relationship between blood lipid levels, asthma, lung function, sensitization and allergic rhinitis in 296 7-year-old children born to mothers with a diagnosis of asthma.
Increasing LDL-cholesterol levels were associated with a 93% increase in the odds of concurrent asthma after adjustment and a significantly increased risk of airway obstruction, the researchers reported July 3 in the Journal of Allergy and Clinical Immunology.
In contrast, high HDL-cholesterol levels were associated with significantly improved airway flow, decreased bronchial responsiveness, 73% lower odds of sensitization against aeroallergens, and a non-significant reduced risk of allergic rhinitis.
High triglyceride levels were significantly associated with a doubling of the risk of aeroallergen sensitization, but not with the other measures.
Dr. Bisgaard said there are no immediate clinical implications of these findings.
"The study is seeking to understand the origins and mechanisms of chronic inflammatory disorders such as asthma and allergy," he said. "This insight will build the foundation for future prevention and treatment."
The researchers add, "Further longitudinal studies are required to evaluate a potential modifiable link between an unhealthy blood lipid profile and asthma and allergic sensitization."
Dr. Yang-Ching Chen from Taipei City Hospital in Taiwan, who was not involved in the new work, also found a link between LDL-cholesterol and asthma in an earlier study.
"Our data identified a trend of increasing levels of total cholesterol and LDL-cholesterol in the group order obese asthmatics > non-obese asthmatics > obese controls > non-obese...Read more..
The COPD Foundation is extremely pleased to announce that a new clinical biomarker, plasma fibrinogen, has been approved for use in interventional clinical trials in patients with chronic obstructive pulmonary disease, the nation’s 3rd leading cause of death. This is the first COPD biomarker to receive qualification by the U.S. Food and Drug Administration (FDA) and is the result of six years of work by the COPD Biomarker Qualification Consortium (CBQC).
“Individuals working in the pharmaceutical industry, universities and the patient community have spent several million dollars and countless hours assembling and analyzing data that has led to the FDA’s monumental decision to approve this first COPD biomarker. Ultimately this clinical biomarker will enable future drug development to benefit patients.”
The CBQC, which includes representatives and resources from university and government research, pharmaceutical and patient communities, was created by the COPD Foundation in 2010, with encouragement from the FDA and the National Heart, Lung and Blood Institute, to develop a “biomarker qualification process” for COPD. Biomarkers are medical processes that researchers use to measure disease severity or to determine if a new drug or treatment is effective. Being able to use a biomarker qualified by the FDA assures drug developers that any potential new drug applications will not be rejected simply because of how the drug’s efficacy was measured or how patients were selected.
“This is a major triumph and, on behalf of the entire COPD community, I extend a heart-felt thank you to the FDA and congratulate the CBQC on its commitment and tireless leadership that allowed us to reach this significant milestone,” said John W. Walsh, co-founder and president of the COPD Foundation. “Individuals working in the pharmaceutical industry, universities and the patient community have spent several million dollars and countless hours assembling and analyzing data that has led to the FDA’s monumental decision to approve this first COPD biomarker. Ultimately this clinical biomarker will enable future drug development to benefit patients.”
COPD causes serious long-term disability and as many as 24 million Americans have the disease, but approximately half of them remain undiagnosed. On average, one American dies from COPD every 4 minutes yet in the last 3 decades, only one new class of drug has been approved for COPD.
For more information...Read more..
There may be 35 million older Americans with undiagnosed lung disease due to cigarette smoking, a new study suggests.
They don't meet the criteria for a diagnosis of chronic obstructive pulmonary disease (COPD), but they still suffer significant lung disease and impairment, the researchers report in JAMA Internal Medicine.
"We think we can increase their quality of life by treating them before they get worse," said Dr. James Crapo, the study's senior author from National Jewish Health in Denver.
Currently, about half of U.S. residents age 49 and older are current or former cigarette smokers, the researchers write.
About one in five U.S. adults currently smoke.
COPD, the third leading cause of death in the U.S., is often related to smoking, they add. The disease worsens with age and makes it more and more difficult to breathe.
Typically, the condition is diagnosed through spirometry, which measures lung function. But Crapo points out that lung function can be impaired to lesser degrees before people qualify for a COPD diagnosis.
For the new study, the researchers looked at data from people across the U.S. that had been gathered through spirometry, CT imaging scans of the chest, a walking test and questionnaires.
The researchers compared 4,388 people with normal spirometry tests to 794 people with mild COPD and 108 people who never smoked.
Overall, about 54 percent of people who had normal spirometry scores had signs of lung disease or impairment, the researchers found.
"I think to say they don’t have the disease is wrong," Crapo said.
Compared to the never smokers, those with normal spirometry but impaired lung function had worse quality of life scores, more trouble walking and evidence of airway thickening and emphysema on their CT scans.
The researchers suggest the current diagnostic criteria for COPD may not be picking up everyone with lung disease. Also, the criteria might not detect disease that is progressing in younger smokers.
"We don’t know how to prevent it yet, but the first step is identifying it early," Crapo said. "Then, trying to stop it from progressing."
For now, Crapo said old Americans may qualify for a free CT scan of their chest through Medicare, the public insurance program for older and disabled Americans.
While that scan can help doctors look for cancer, Crapo said it also reveals signs of COPD, such as thickening air walls.
"If you’re one of those people who smoked heavily in...Read more..
The higher the power of an e-cigarette, the higher the concentrations of potentially hazardous substances the device produces, including acetaldehyde, acrolein, and formaldehyde.
Those are among the findings presented at an international conference of the American Thoracic Society by lead study author Dr. Daniel Sullivan, an internal medicine resident at the University of Texas Southwestern Medical Center. During his previous training at the University of Alabama, Birmingham, Dr. Sullivan and his associates used a variety of methods including liquid chromatography–mass spectrometry and enzyme-linked immunosorbent assay (ELISA) to study components and nicotine formulations typical of e-cigarette users.
Under some test conditions, formaldehyde levels were comparable to those seen in traditional tobacco cigarettes, he said in a video interview.
Researchers from the University of Texas Medical Branch at Galveston have found, for the first time, that spirometry was underutilized for asthma diagnosis and management in U.S. adults from 2001 to 2011, despite it's accuracy, cost effectiveness and the publication of national guidelines advocating its use.
Spirometry is a common test that allows physicians to determine how well a person's lungs work by measuring how much air is inhaled and exhaled as well as how quickly the air is exhaled. This test plays a vital role in the diagnosis and management of asthma by providing accurate measurements of air volumes and flows.
The Choosing Wisely initiative of the American Board of Internal Medicine Foundation helps physicians and patients work together to make appropriate, effective and cost-effective health care choices.
Asthma affects about 8 percent of U.S. adults, which cost $56 billion in medical care in 2007. The Choosing Wisely initiative recommends spirometry for diagnosis and follow-up asthma care because it's effective and costs about $42. On the other hand, unnecessary use of an inhaler can cost $200 to $300 a month. An emergency room visit for an asthma episode can total $3,500. Health care use, including emergency department visits and hospitalizations are linked with how well asthma is controlled. Thus, when used in the diagnosis and management of asthma at the recommended times, spirometry should prevent needless expense.
This study evaluated trends, from 2001 to 2011, in the use of spirometry in patients within a year of when they were diagnosed with asthma. The findings are detailed in the American Journal of Medicine.
In all, 134,208 asthma patients were included in the study. Only 48 percent had spirometry performed within one year of diagnosis. Younger patients, males and those residing in the Northeast were more likely to receive spirometry. Eighty percent of patients cared for by specialists received spirometry, while only 23 percent of those cared for by primary care physicians underwent the test. However, even without spirometry, close to 80 percent of patients were prescribed asthma drugs.
"Physicians must be educated about the usefulness of spirometry and given evidence of its medical and monetary value," said Dr. Kristin Sokol, assistant professor of pediatrics in the division of allergy and immunology. "As the Choosing Wisely initiative implies, the underuse of spirometry may lead to misdiagnosis or under...Read more..
In the Issue of the New England Journal of Medicine an investigation of the role of financial incentives and nudges in promoting smoking cessation, with particular emphasis on the importance of loss aversion and pre-commitment is explored.
In the past 40 years, we have seen a revolution in thinking about thinking. The central idea is that human beings depart, in systematic ways, from standard economic approaches to rationality. Because the departures are systematic and predictable, they can be taken into account by researchers, clinicians, and others who want to improve health and reduce premature mortality.
Behavioral scientists have shown, for example, that people are “loss averse”; they tend to dislike losses more than they like corresponding gains. A 5-cent tax on the use of a grocery bag is likely to have a much greater effect than a 5-cent bonus for bringing one’s own bag. People also suffer from “present bias”: they tend to focus on the short term and sometimes see the future as a kind of foreign country (and their future selves as strangers). Most people tend to be unrealistically optimistic, at least about their own prospects. People are sometimes aware of their own biases and are willing to pre-commit to courses of action that will counteract them.
These and related findings help to explain preventable health problems and also suggest a wide range of potentially promising interventions. Some such interventions involve economic incentives, in the form of subsidies and penalties. Others involve “nudges,” in the form of choice-preserving interventions that do not impose any such incentives; information, warnings, reminders, and default rules are examples of nudges. Still other interventions combine the two, as with nudges designed to encourage people to enter programs that impose economic incentives.
In this issue of the Journal, Halpern and his colleagues investigate the role of financial incentives and nudges in promoting smoking cessation, with particular emphasis on the importance of loss aversion and pre-commitment. They explore two kinds of interventions for CVS Caremark employees and their relatives and friends. The first is a “deposit program,” in which smokers deposit $150, which they can get back if they stop smoking, along with $650 extra. The second is a “reward program,” in which people receive $800 if they stop smoking. Halpern et al. are interested above all in two questions. First, when will...Read more..
MD Spiro prides itself on not only offering incredible spirometry products for your practice, but also prides itself on providing articles and industry updates for our customers. Below is a new study showing you trends, R&D progress, and predicted revenues in Asthma and COPD Therapies.
So where’s the asthma and COPD therapies market heading? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.
This 335-page report provides 264 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. This new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharma market.
Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter's Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of six exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
- Clive Page, Professor of Pharmacology, King's College London
- Monica Fletcher, Chief Executive, Education for Health
- Daphne Tsitoura, Senior Medical Director, GSK
- Barbara Yawn, Director of Research, Olmsted Medical Center
- Ahmed Wagih, Product Manager, Respiratory Franchise, GSK
Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you see forecasts to 2024 for the following submarkets:
- Bronchodilator monotherapy – SABAs, LABAs, anticholinergic drugs
- Anti-inflammatory drugs – inhaled corticosteroids, anti-leukotrienes, monoclonal antibodies
- Combination drugs.
Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.
See revenue forecasts for products
How will leading drugs and promising products currently in development perform to 2024 at world level? Our study...